CASI Pharmaceuticals (CASI) Competitors

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.

Do analysts recommend EPRX or CASI?

Eupraxia Pharmaceuticals currently has a consensus price target of $10.50, indicating a potential upside of 174.15%. CASI Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 151.05%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.50
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor EPRX or CASI?

In the previous week, Eupraxia Pharmaceuticals and Eupraxia Pharmaceuticals both had 1 articles in the media. CASI Pharmaceuticals' average media sentiment score of 0.94 beat Eupraxia Pharmaceuticals' score of 0.63 indicating that CASI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better valuation & earnings, EPRX or CASI?

CASI Pharmaceuticals has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$28.22M	-$0.72	-5.32
CASI Pharmaceuticals	$22.06M	1.68	-$26.94M	-$2.23	-1.07

Do insiders and institutionals hold more shares of EPRX or CASI?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is EPRX or CASI more profitable?

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. CASI Pharmaceuticals' return on equity of -181.52% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-219.64%	-96.00%
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%

Does the MarketBeat Community believe in EPRX or CASI?

CASI Pharmaceuticals received 196 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 49.63% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Eupraxia Pharmaceuticals	Outperform Votes 4 100.00%	Underperform Votes No Votes
CASI Pharmaceuticals	Outperform Votes 200 49.63%	Underperform Votes 203 50.37%

Summary

CASI Pharmaceuticals beats Eupraxia Pharmaceuticals on 9 of the 16 factors compared between the two stocks.